Peter Nash
0000-0002-2571-788X
Griffith University
193 papers found
Refreshing results…
Current Treatment Strategies in Rheumatoid Arthritis After Methotrexate Are Not Enough to Maintain Sustained Remission: There Is No Holy Grail!
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
Clinical use of Jak 1 inhibitors for rheumatoid arthritis
Response to: ‘Correspondence on ‘Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement’’ by Bandayet al
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
Real-world Evidence Needs Careful Interpretation
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
How Can We Improve the Use of Established Therapies in PsA?
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Comparison of Remission and Low Disease activity states with DAPSA, MDA and VLDA in a Clinical Trial Setting in Psoriatic Arthritis Patients: 2-year Results from the FUTURE 2 Study
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies
A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAiVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-Week EFFICACY AND SAFETY OUTCOMES FROM a RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY
Secukinumab Provides Sustained Improvement in Nail Psoriasis and Inhibition of Radiographic Progression in Psa Patients With Nail Phenotype: 52-Week Results From a Phase 3 Study
Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study
Comparison of Different Remission Indices in Patients With Psoriatic Arthritis: A Post Hoc Analysis of Data From Phase 3 Tofacitinib Studies
2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviews
Secukinumab Efficacy in Psoriatic Arthritis
Missing publications? Search for publications with a matching author name.